Pharmaceutical Company Invests in Beihui Bio-Peak Pharmaceutical Plate to Expand its Territory
Release time:
2020-07-31
News from this newspaper 2# March 28 , the 10 meeting of the ninth board of directors of the group company deliberated and passed the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing the Chairman". On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation.
Beihui Biology was formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through cooperation with Yale University, we have obtained patent authorization and commercial development license for the new anticancer chemical drug troxacitabine (trokacitabine )(the national clinical approval for the new drug has been obtained in 2016 ), the anti-hepatitis B chemical drug clevudine (Clevudine ).
Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biological Holding Company, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly established by the Chinese government and foreign governments in Guangxi. It covers an area of 214.46 mu and has basically completed the production workshops of percolation, tincture, solid preparation, liquid preparation and other dosage forms, at present, it has entered the GMP certification stage. Guanghui Pharmaceutical has 77 drug approvals mainly for proprietary Chinese medicine preparations. Its main products include Huoxiang Zhengqi Water, Shidishui, Chen Xianglu Bailu Tablets, Compound Pearl Jiedu Oral Liquid, Yigan Mingmu Oral Liquid, etc. Among them, Yigan Mingmu Oral Liquid and Pearl Jiedu Oral Liquid are exclusive products.
According to the cooperation agreement, when the agreed preconditions are met, Jianfeng Pharmaceutical plans to increase the capital of Beihui Biology in four phases. After the agreement comes into effect, it will make the first phase of investment and will contribute ,000 yuan to increase the capital of Beihui Biology in 2,000 shares (accounting for 20% of shares); the second phase contributed ,8600 yuan to increase ,2000 shares of Beihui Biology, and at the same time contributed ,3010 yuan to transfer ,700 shares of Beihui Biology. In the third and fourth phases, the capital increase was ,1400 shares respectively. The capital increase price was determined through negotiation based on the evaluation value of Beihui Biology at that time. If the capital increase and equity transfer are all completed, Peak Pharmaceuticals will hold Beihui Bio 7500 shares (accounting for 50.68% of the equity, the calculation of the equity ratio does not take into account the introduction of other investors). The next few phases of investment will be implemented in stages according to the investment prerequisites agreed in the agreement, the progress of product development, the operation of the target company and other factors.
This cooperation is based on the company's strategic policy of "cooperating and innovating to strengthen the main business, standardizing science and seeking development". It is the specific implementation of expanding and strengthening the pharmaceutical business, which will help to further enhance the new drug research and development capability of Jianfeng Pharmaceutical and further expand the scale of the company's pharmaceutical business. (Zhou Hengbin)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page